{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:21:09Z","timestamp":1793575269739,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1136\/ard-2023-224803","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T13:20:14Z","timestamp":1696425614000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-118X","authenticated-orcid":false,"given":"Huji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Massow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fleurinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Shepherd-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-5336","authenticated-orcid":false,"given":"Lianne S","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224803_bib1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient burden of axial spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard-2023-224803_bib3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic Sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1759720X17706454","article-title":"Tumor necrosis factor-\u0391 (TNF\u03b1) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy","volume":"9","author":"Rios Rodriguez","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2023-224803_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo\u2010controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224803_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of Ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/ph15030270","article-title":"The use of Janus kinase inhibitors in axial spondyloarthritis: current insights","volume":"15","author":"Toussirot","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1136\/ard-2023-224803_bib8","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/ard.2004.035105","article-title":"Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks","volume":"64","author":"Davis","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib9","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo\u2010controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224803_bib10","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double\u2010blind, placebo\u2010controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224803_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/14712598.2022.2156283","article-title":"Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis","volume":"23","author":"Braun","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"10.1136\/ard-2023-224803_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-224803_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1136\/ard-2023-224803_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy","volume":"16","author":"van Baarsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224803_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210305","article-title":"Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies","volume":"24","author":"S\u00e1nchez-Rodr\u00edguez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ard-2023-224803_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585134","article-title":"Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling","volume":"11","author":"Cole","year":"2020","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224803_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/BOR.0000000000000805","article-title":"Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis","volume":"33","author":"Yeremenko","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard-2023-224803_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel Humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-224803_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224803_bib22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib23","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.42282","article-title":"Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase IIb randomized controlled trial and its open-label extension study","volume":"74","author":"Baraliakos","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224803_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis International society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1136\/ard-2023-224803_bib25","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","article-title":"Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group","volume":"75","author":"Lambert","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224803_bib27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.21563","article-title":"Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial","volume":"54","author":"Haibel","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224803_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.21445","article-title":"Spondyloarthritis research consortium of Canada magnetic resonance imaging index for assessment of Sacroiliac joint inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224803_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/kev267","article-title":"ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis","volume":"55","author":"van der Heijde","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224803_bib30","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","article-title":"The ASAS-OMERACT core domain set for axial spondyloarthritis","volume":"51","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224803_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"The Lancet"},{"key":"10.1136\/ard-2023-224803_bib32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2022-eular.5016","article-title":"LB0001 Bimekizumab in bDMARD-naive patients with psoriatic arthritis: 24-week efficacy & safety from BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study","volume":"81","author":"Mcinnes","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"The Lancet"},{"key":"10.1136\/ard-2023-224803_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/annrheumdis-2022-eular.892","article-title":"POS0074 immunological differences between PSA patients who are tumor necrosis factor inhibitor-naive and who have inadequate response to tumor necrosis factor inhibitors","volume":"81","author":"Siebert","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"The Lancet"},{"key":"10.1136\/ard-2023-224803_bib36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of Interleukin-17A and Interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIB, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224803_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/jof3040052","article-title":"The role of IL-17 in protection against mucosal Candida infections","volume":"3","author":"Mengesha","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"10.1136\/ard-2023-224803_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard-2023-224803_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1136\/ard-2023-224803_bib40","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-2-1","article-title":"Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors","volume":"9","author":"Fieldhouse","year":"2020","journal-title":"Drugs Context"},{"key":"10.1136\/ard-2023-224803_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-Articular disease in Ankylosing Spondylitis versus non-radiographic axial Spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224803_bib42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2217\/imt.13.87","article-title":"Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis","volume":"5","author":"McLean","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1136\/ard-2023-224803_bib43","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1097\/MIB.0b013e318286fa1c","article-title":"TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis","volume":"19","author":"Wedebye Schmidt","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/ard-2023-224803_bib44","first-page":"614","article-title":"POS0668 low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2B\/3 trials","volume":"82","author":"Rudwaleit","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724080130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724080130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:03:51Z","timestamp":1786201431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724080130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0003496724080130"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224803","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 The authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}